Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceuticals has raised $175.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2025.
Amylyx Pharmaceuticals's investors include Alpha Wave Global, Perceptive Advisors, Bain Capital Life Sciences, Rock Springs Capital, Viking Global Investors.
Amylyx Pharmaceuticals is headquartered in Cambridge, United States.
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amylyx Pharmaceuticals — Funding & Investors." VCBacked, September 10, 2025, https://www.vcbacked.co/company/amylyx-pharmaceuticals. Accessed September 29, 2026.
VCBacked. (2025). Amylyx Pharmaceuticals — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/amylyx-pharmaceuticals
{{cite web |title=Amylyx Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/amylyx-pharmaceuticals |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated